Inhaltsbereich
| 16 Einträge |
Seite 1 / 1
 Druckansicht
|
| Sphaeropsidin A shows promising activity against drug-resistant cancer cells by targeting regulatory volume increase. |
| Mathieu V, Chantôme A, Lefranc F, Cimmino A, Miklos W, Paulitschke V, Mohr T, Maddau L, Kornienko A, Berger W, Vandier C, Evidente A, Delpire E, Kiss R |
| Cellular and molecular life sciences : CMLS. 2015 Apr 14. doi: 10.1007/s00018-015-1902-6. pii: 10.1007/s00018-015-1902-6 |
| PMID: 25868554 |
| Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts. |
| Paulitschke V, Berger W, Paulitschke P, Hofstätter E, Knapp B, Dingelmaier-Hovorka R, Födinger D, Jäger W, Szekeres T, Meshcheryakova A, Bileck A, Pirker C, Pehamberger H, Gerner C, Kunstfeld R |
| Molecular cancer therapeutics. 2015 Jan 22. pii: 1535-7163.MCT-14-0701. doi: 10.1158/1535-7163.MCT-14-0701 |
| PMID: 25612618 |
| Proteome profiling of keratinocytes transforming to malignancy. |
| Paulitschke V, Gerner C, Hofstätter E, Mohr T, Mayer RL, Pehamberger H, Kunstfeld R |
| Electrophoresis. 2015 Jan 28. doi: 10.1002/elps.201400309 |
| PMID: 25395074 |
| Plasticity of fibroblasts demonstrated by tissue-specific and function-related proteome profiling. |
| Slany A, Meshcheryakova A, Beer A, Ankersmit HJ, Paulitschke V, Gerner C |
| Clinical proteomics. 2014 Nov 21. doi: 10.1186/1559-0275-11-41. pii: 89. pmc: PMC4448269 |
| PMID: 26029019 |
| Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells. |
| Paulitschke V, Haudek-Prinz V, Griss J, Berger W, Mohr T, Pehamberger H, Kunstfeld R, Gerner C |
| Journal of proteome research. 2013 Jun 19. doi: 10.1021/pr400124w. pmc: PMC3733130 |
| PMID: 23713901 |
| Proteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction. |
| Paulitschke V, Gruber S, Hofstätter E, Haudek-Prinz V, Klepeisz P, Schicher N, Jonak C, Petzelbauer P, Pehamberger H, Gerner C, Kunstfeld R |
| PloS one. 2012 Sep 25. doi: 10.1371/journal.pone.0046103. pii: PONE-D-12-07567. pmc: PMC3458105 |
| PMID: 23049949 |
| 3,3',4,4',5,5'-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model. |
| Paulitschke V, Schicher N, Szekeres T, Jäger W, Elbling L, Riemer AB, Scheiner O, Trimurtulu G, Venkateswarlu S, Mikula M, Swoboda A, Fiebiger E, Gerner C, Pehamberger H, Kunstfeld R |
| The Journal of investigative dermatology. 2009 Dec 3. pii: jid2009376. doi: 10.1038/jid.2009.376 |
| PMID: 19956188 |
| Introducing the CPL/MUW proteome database: interpretation of human liver and liver cancer proteome profiles by referring to isolated primary cells. |
| Wimmer H, Gundacker NC, Griss J, Haudek VJ, Stättner S, Mohr T, Zwickl H, Paulitschke V, Baron DM, Trittner W, Kubicek M, Bayer E, Slany A, Gerner C |
| Electrophoresis. 2009 Jul 14. doi: 10.1002/elps.200900072 |
| PMID: 19582709 |
| Erlotinib and bevacizumab have synergistic activity against melanoma. |
| Schicher N, Paulitschke V, Swoboda A, Kunstfeld R, Loewe R, Pilarski P, Pehamberger H, Hoeller C |
| Clinical cancer research : an official journal of the American Association for Cancer Research. 2009 May 15. pii: 1078-0432.CCR-08-2407. doi: 10.1158/1078-0432.CCR-08-2407 |
| PMID: 19447871 |
| Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells. |
| Paulitschke V, Kunstfeld R, Mohr T, Slany A, Micksche M, Drach J, Zielinski C, Pehamberger H, Gerner C |
| Journal of proteome research. 2009 Jun 3. doi: 10.1021/pr8010827. pii: 10.1021/pr8010827 |
| PMID: 19222175 |
| Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma. |
| Paulitschke V, Eichhoff O, Cheng PF, Levesque MP, Höller C |
| Current opinion in oncology. 2016 Jan 6. doi: 10.1097/CCO.0000000000000261 |
| PMID: 26742019 |
| Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases. |
| Zila N, Bileck A, Muqaku B, Janker L, Eichhoff OM, Cheng PF, Dummer R, Levesque MP, Gerner C, Paulitschke V |
| Clinical proteomics. 2018 Mar 9. doi: 10.1186/s12014-018-9189-x. pii: 9189. pmc: PMC5844114 |
| PMID: 29541007 |
| Proteomic identification of a marker signature for MAPKi resistance in melanoma. |
| Paulitschke V, Eichhoff O, Gerner C, Paulitschke P, Bileck A, Mohr T, Cheng PF, Leitner A, Guenova E, Saulite I, Freiberger SN, Irmisch A, Knapp B, Zila N, Chatziisaak TP, Stephan J, Mangana J, Kunstfeld R, Pehamberger H, Aebersold R, Dummer R, Levesque MP |
| The EMBO journal. 2019 Jun 26. doi: 10.15252/embj.201695874 |
| PMID: 31267558 |
| Cutaneous manifestations of acute and chronic graft-versus-host disease. |
| Cho A, Paulitschke V, Just U, Knobler R |
| Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia. pii: S0392-0488.19.06535-0. doi: 10.23736/S0392-0488.19.06535-0 |
| PMID: 32100975 |
| Systematic Analysis of the Transcriptome Profiles and Co-Expression Networks of Tumour Endothelial Cells Identifies Several Tumour-Associated Modules and Potential Therapeutic Targets in Hepatocellular Carcinoma. |
| Mohr T, Katz S, Paulitschke V, Aizarani N, Tolios A |
| Cancers. 2021 Apr 7. pii: cancers13081768. doi: 10.3390/cancers13081768 |
| PMID: 33917186 |
| ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in NRAS-Mutated Melanoma. |
| Eichhoff OM, Stoffel CI, Käsler J, Briker L, Turko P, Karsai G, Zila N, Paulitschke V, Cheng PF, Leitner A, Bileck A, Zamboni N, Irmisch A, Balazs Z, Tastanova A, Pascoal S, Johansen P, Wegmann R, Mena J, Othman A, Viswanathan VS, Wenzina J, Aloia A, Saltari A, Dzung A, Krauthammer M, Schreiber SL, Hornemann T, Distel M, Snijder B, Dummer R, Levesque MP |
| Cancer research. 2023 Mar 22. doi: 10.1158/0008-5472.CAN-22-1826. pii: 718846 |
| PMID: 36946761 |
| 16 Einträge |
Seite 1 / 1
Druckansicht
|
Schnellinfo
-- Initiative Krebsforschung / Krebsforschungslauf
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
-- Cancer Care
-- Kliniken und Partner
-- CCC Cancer School
-- Young CCC
-- CCC Tumorboards
-- CCC Forschungscluster
-- CCC Units
-- CCC Platforms
-- SOPs / Leitlinien
-- Kontakt
Featured
